Novartis: CVAY736Y2102 Ph1b VAY736 and Ibrutinib patients with CLL on Ibrutinib therapy
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
February 1, 2020
End Date
February 28, 2021
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
February 1, 2020
End Date
February 28, 2021